Format

Send to

Choose Destination
Sci Rep. 2018 Mar 19;8(1):4802. doi: 10.1038/s41598-018-23037-7.

Potential role of new molecular plasma signatures on cardiovascular risk stratification in asymptomatic individuals.

Author information

1
Department of Vascular Physiopathology, Hospital Nacional de Paraplejicos (HNP), SESCAM, Toledo, Spain.
2
Cardiovascular Proteomics Laboratory and CIBER-CV, CNIC, Madrid, Spain.
3
Departament of Immunology, IIS-Fundacion Jimenez Diaz, Madrid, Spain.
4
Laboratory of Hypertension and Cardiovascular Risk, Instituto de Investigación i+12, Hospital Universitario 12 de Octubre, Madrid, Spain.
5
Ibermutuamur, Madrid, Spain.
6
Departamento de Bioquimica y Biologia Molecular I, Universidad Complutense, Madrid, Spain.
7
Departamento de Cardiologia, Complejo Hospitalario de Toledo, SESCAM, Toledo, Spain.
8
Laboratory of Hypertension and Cardiovascular Risk, Instituto de Investigación i+12, Hospital Universitario 12 de Octubre, Madrid, Spain. ruilope@icloud.com.
9
Department of Preventive Medicine and Public Health, School of Medicine, Universidad Autónoma de Madrid/IdiPAZ and CIBER in Epidemiology and Public Health (CIBERESP), Madrid, Spain. ruilope@icloud.com.
10
School of Doctoral Studies and Research, Universidad Europea de Madrid, Madrid, Spain. ruilope@icloud.com.
11
Department of Vascular Physiopathology, Hospital Nacional de Paraplejicos (HNP), SESCAM, Toledo, Spain. megonzalezb@sescam.jccm.es.

Abstract

The evaluation of cardiovascular (CV) risk is based on equations derived from epidemiological data in individuals beyond the limits of middle age such as the Framingham and SCORE risk assessments. Lifetime Risk calculator (QRisk®), estimates CV risk throughout a subjects' lifetime, allowing those. A more aggressive and earlier intervention to be identified and offered protection from the consequences of CV and renal disease. The search for molecular profiles in young people that allow a correct stratification of CV risk would be of great interest to adopt preventive therapeutic measures in individuals at high CV risk. To improve the selection of subjects susceptible to intervention with aged between 30-50 years, we have employed a multiple proteomic strategy to search for new markers of early CV disease or reported CV events and to evaluate their relationship with Lifetime Risk. Blood samples from 71 patients were classified into 3 groups according to their CV risk (healthy, with CV risk factors and with a previously reported CV event subjects) and they were analyzed using a high through quantitative proteomics approach. This strategy allowed three different proteomic signatures to be defined, two of which were related to CV stratification and the third one involved markers of organ damage.

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for PubMed Central
Loading ...
Support Center